Jade Biosciences, Inc.·4

Jul 14, 7:12 PM ET

Dahms Bradford D. 4

4 · Jade Biosciences, Inc. · Filed Jul 14, 2025

Insider Transaction Report

Form 4
Period: 2025-07-14
Dahms Bradford D.
Chief Financial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-07-14+526,000526,000 total
    Exercise: $9.00Exp: 2035-07-14Common Stock (526,000 underlying)
Footnotes (1)
  • [F1]This option represents a right to purchase 526,000 shares of the Issuer's common stock, one quarter of which will vest on July 14, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4